Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929556 | 1.00 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2CYP2C19HIF1ABLM | |
| SCHEMBL20143336 | 0.88 | SMN1; SMN2 (0.50) | L3MBTL1SMN1; SMN2BLMCYP2D6HDAC6 | |
| SCHEMBL745452 | 0.86 | CYP2C19 (0.56) | L3MBTL1SMN1; SMN2CYP2C19HIF1ABLM | |
| SCHEMBL17743682 | 0.86 | CYP2C19 (0.47) | L3MBTL1SMN1; SMN2CYP2C19HIF1ABLM | |
| SCHEMBL28291731 | 0.83 | SMN1; SMN2 (0.46) | L3MBTL1SMN1; SMN2BLMCYP2D6HDAC6 | |
| SCHEMBL4491943 | 0.82 | CETP (0.45) | L3MBTL1SMN1; SMN2BLMCYP2D6HDAC6 | |
| SCHEMBL5929588 | 0.81 | L3MBTL1 (0.47) | L3MBTL1SMN1; SMN2CYP2C19HIF1ABLM | |
| SCHEMBL28291723 | 0.81 | LMNA (0.50) | L3MBTL1SMN1; SMN2CYP2C19BLMCYP2D6 | |
| SCHEMBL28872854 | 0.81 | CETP (0.47) | L3MBTL1SMN1; SMN2LMNAPOLBTSHR | |
| SCHEMBL21631937 | 0.80 | CYP2C19 (0.50) | L3MBTL1SMN1; SMN2CYP2C19HIF1ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969858-B2 | Metalloinsertor conjugates | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969858-B2 | Metalloinsertor conjugates | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969858-B2 | Metalloinsertor conjugates | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160222043-A1 | METALLOINSERTOR CONJUGATES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-08-04 | — | — | US | disclosed |
| US-20160222043-A1 | METALLOINSERTOR CONJUGATES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-08-04 | — | — | US | disclosed |
| US-20160222043-A1 | METALLOINSERTOR CONJUGATES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-08-04 | — | — | US | disclosed |
| EP-1489070-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222043-A1 | METALLOINSERTOR CONJUGATES | MSH2, MSH6, LIG1 | L3MBTL1 8/4885SMN1; SMN2 285/4885CYP2C19 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.